Therapy Areas: Hereditary Disorders
Oxford BioMedica collaborates with UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations
8 August 2018 -

United Kingdom-based Oxford BioMedica has collaborated with the UK Cystic Fibrosis Gene Therapy Consortium and United Kingdom-based Imperial Innovations.

It was reported yesterday that the collaboration is aimed at the development of a long-term therapy to treat patients with cystic fibrosis. It will use a novel and replication deficient lentiviral vector in an inhaled formulation to selectively introduce a CFTR gene into the relevant target cell. It is also planning to assess Oxford BioMedica's transgene repression in vector production system and develop stable producer cell lines for large scale production of the lentiviral vector.

According to the terms of the process development collaboration agreement, Oxford BioMedica will involve in the process and analytical development, increase manufacture of the candidate and generation of material for toxicology studies.



Related Headlines